A Single-Arm, Prospective Study of a Proprietary Synthetic Acellular Self-Assembling Peptide Wound Matrix, AC5® Advanced Wound System, for Treatment of Hard-to-Heal Wounds

Le résumé fourni par la source

INTRODUCTION: When wounds do not respond to standard treatments, advanced therapies are recommended. One such therapy, a proprietary synthetic peptide, self-assembles into a wound matrix when applied to a wound to provide a physical-mechanical barrier that mitigates contamination, modulates inflammation, and becomes a scaffold for cell proliferation and growth. This study evaluated the safety and performance of the AC5 ® Advanced Wound System (Arch Therapeutics Inc. Framingham, Massachusetts) in the management of long-duration, non-healing, and challenging acute and chronic wounds that failed prior therapy. MATERIALS AND METHODS: Fifteen participants were assigned to receive treatment with AC5 ® weekly or every other week. AC5 ® was evaluated for ease of use, and participants were evaluated for wound condition, healing progress, and local and systemic adverse reactions. RESULTS: 64% of participants treated weekly had a >50% reduction in wound area at four weeks and 73% had a >60% reduction at eight weeks. For patients treated every other week, 25% achieved 50% wound area reduction at four weeks and 50% had a >50% reduction at eight weeks. The product was easy to apply contiguously to uneven wound geometry. There were no adverse events. CONCLUSION: The synthetic self-assembling peptide wound matrix was shown to be safe, effective, and simple to use in the treatment of hard-to-heal wounds. Because AC5® is easy to apply, has an unusual ability to self-assemble into a wound matrix in vivo, and affixes itself contiguously to the interstices of the tissue, AC5 ® may be particularly useful for undermined and tunneled wounds, whether acute or chronic. The results of this study imply that a once-weekly application may result in the best outcome. Further studies are suggested to confirm optimal application frequency for different wound types.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.